Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...

Royalty Pharma (RPRX) announced that it has acquired the final portion of PTC Therapeutics’ remaining royalty on Roche’s (RHHBY) Evrysdi for $240M ...

What defined pharma in 2025? Contract Pharma’s most‑viewed breaking news offers insights. Here’s your yearly recap—the most ...

Discover why pharma sector leaders and AI innovation may drive the S&P 500 to 9,000 by 2026. Explore top stocks, growth ...

The deal announced Friday tacks on to similar reduced price agreements the Trump administration has made with five other ...

Check out a month-by-month breakdown of the major events affecting the pharma and medical marketing industries in 2025.

Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 ...

Large pharmaceutical companies are entering a period of renewed relevance as therapeutic innovation accelerates, particularly ...

“Healthcare and pharma are steadily moving past a TV-first mindset. While linear TV made up more than 30% of the industry’s ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a conference call on Thursday, November 13, 2025, at 2 p.m. CET / 8 a.m. ET, ...

Martin Shkreli, the notorious former CEO of Turing Pharmaceuticals and convicted securities fraudster, will still be banned from working in the pharmaceutical industry after a federal appeals court in ...